SHP1-IN-2 

SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8^＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research^[1].

SHP1-IN-2 (M029) (up to 50 μM; 24-72 h) shows no obvious cytotoxicity in Jurkat T, HEK293, MC38, EO771, B16-F10, and Raw264.7 cells^[1].
SHP1-IN-2 (0-20 μM; Anti-CD3 Antibody (OKT-3) (HY-P990864) stimulation for 10 min) enhances the phosphorylation of LCK, PLCγ, and ERK1/2 and promotes IL-2 production in TCR-stimulated Jurkat T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SHP1‑IN‑2 (M029) (25 mg/kg, 100 mg/kg; once daily) significantly suppresses tumor growth in MC38 colon cancer syngeneic mouse models^[1].
SHP1‑IN‑2 (25 mg/kg; once daily) increases infiltration and activation of NK cells and CD8⁺ T cells, reduces the proportion of PD-1⁺ TIM3⁺ exhausted T cells in MC38 tumor tissues, shows no obvious toxicity or body weight loss in tumor‑bearing mice, and loses antitumor efficacy in CD8⁺ T cell‑depleted mice and nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

355.82

C₁₃H₁₀ClN₃O₃S₂

O=S(C1=CC=C(NC(CCl)=O)C=C1)(NC2=C(C#N)C=CS2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Qu Z, et al. Discovery of a First-in-Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity. Angew Chem Int Ed Engl. 2026;65(7):e25126.